Experimental vaccine combo takes on tough pancreatic cancer
NCT ID NCT07637786
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new peptide nanovaccine (ONVAX-01) together with an anti-PD-1 antibody and standard chemotherapy in 9 people with advanced pancreatic cancer that has worsened after prior treatment. The main goals are to see if the combination is safe and whether it can shrink tumors or stop the cancer from growing. Participants receive the vaccine as a shot under the skin and the other drugs through an IV, along with regular checkups and scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- peptide nanovaccine (ONVAX-01) plus an anti-PD-1 antibody and chemotherapy
- What this could lead to
- If it works, this could point toward a new combination treatment that shrinks tumors or slows disease progression in advanced pancreatic cancer.
- What could go wrong
- This is a very early phase 1 trial with only 9 participants, so results may not apply broadly. The combination may cause significant side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Pan-RAS inhibitor outsmart pancreatic cancer?
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- Smart drug delivers chemo directly to pancreatic cancer cells
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Drug cocktail aims to stall pancreatic cancer in patients who have run out of options